ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Upgraded by StockNews.com

ANI Pharmaceuticals (NASDAQ:ANIP) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Wednesday.

Several other brokerages have also issued reports on ANIP. Leerink Partners started coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price target on the stock. Truist Financial lifted their price objective on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research report on Tuesday, October 22nd. HC Wainwright reissued a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Piper Sandler began coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They issued an “overweight” rating and a $68.00 price objective for the company. Finally, Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $77.71.

ANI Pharmaceuticals Stock Up 0.6 %

Shares of ANIP stock opened at $60.19 on Wednesday. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals has a 1 year low of $52.50 and a 1 year high of $70.81. The firm’s fifty day moving average price is $56.64 and its two-hundred day moving average price is $58.51. The firm has a market capitalization of $1.27 billion, a P/E ratio of -109.44 and a beta of 0.74.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. During the same period in the previous year, the business earned $1.05 EPS. The company’s revenue was up 12.5% compared to the same quarter last year. On average, equities analysts predict that ANI Pharmaceuticals will post 3.86 EPS for the current fiscal year.

Insider Buying and Selling

In other news, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total value of $60,000.00. Following the completion of the transaction, the senior vice president now directly owns 49,059 shares in the company, valued at approximately $2,943,540. The trade was a 2.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Nikhil Lalwani sold 33,481 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the completion of the transaction, the chief executive officer now owns 370,378 shares of the company’s stock, valued at $21,478,220.22. The trade was a 8.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 42,381 shares of company stock valued at $2,441,556. Company insiders own 12.70% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. State Street Corp increased its position in ANI Pharmaceuticals by 9.1% during the 3rd quarter. State Street Corp now owns 703,843 shares of the specialty pharmaceutical company’s stock worth $41,991,000 after purchasing an additional 58,698 shares in the last quarter. Pacer Advisors Inc. increased its position in ANI Pharmaceuticals by 23,259.8% during the 3rd quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company’s stock worth $33,907,000 after purchasing an additional 565,910 shares in the last quarter. JPMorgan Chase & Co. increased its position in ANI Pharmaceuticals by 159.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock worth $33,101,000 after purchasing an additional 340,854 shares in the last quarter. Global Alpha Capital Management Ltd. increased its position in ANI Pharmaceuticals by 1.8% during the 3rd quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company’s stock worth $32,005,000 after purchasing an additional 9,500 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in ANI Pharmaceuticals by 4.2% during the 3rd quarter. Geode Capital Management LLC now owns 425,225 shares of the specialty pharmaceutical company’s stock worth $25,373,000 after purchasing an additional 17,314 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.